---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-019748"
form_type: "8-K"
ticker: "MAIA"
cik: "0001878313"
company_name: "MAIA Biotechnology, Inc."
filed_at: "2025-10-27T23:59:59+00:00"
generated_at: "2026-05-17T02:13:39.826042+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# MAIA enrolls first five patients in THIO-101 Part C expansion in Taiwan and Turkey

## Summary
- Presented trial-in-progress poster on ateganosine (THIO) plus ICI for advanced NSCLC at AACR-NCI-EORTC conference, Oct 22-26, 2025 in Boston.
- Enrolled first five patients in Part C (expansion) of THIO-101 Phase 2 trial from Taiwan and Turkey.
- Trial evaluates ateganosine (THIO) followed by cemiplimab in 3L NSCLC patients resistant to prior checkpoint inhibitor and chemo.
- Screening ongoing in Europe and Asia with multi-continental sites; safety profile aligned with earlier parts.

## SEC filing metadata
- accession: 0001493152-25-019748
- form_type: 8-K
- ticker: MAIA
- cik: 0001878313
- company_name: MAIA Biotechnology, Inc.
- filed_at: 2025-10-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1878313/000149315225019748/0001493152-25-019748-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1878313/000149315225019748/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-019748
- JSON: https://secwatch.observer/filing/0001493152-25-019748.json
- Plain text: https://secwatch.observer/filing/0001493152-25-019748.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.